http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-596585-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5ec699c96c809fdf202410d55b5cd797
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D261-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D261-02
filingDate 2010-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e663c4c0dfdc0bd995465530c1329e40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02216443700dd378b57bc34d82415567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f23429b974fbcf03cf11a072ebf96eb1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20a7197944f300f0cff54cd6d82c53dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62e8f2978f6a4beba3cc66e240aef1d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7f163af84a39db4124ed843c9ea886a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7f0f406147ea5443214782f9d2946bf6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35977933088fbce980be7a467778c018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b75d9de8c7b3614d858edeab7245e21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b92d568142908a7ee6ad6c4eec380449
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d46031574f532dc161ebbbbbfb6fa17a
publicationDate 2014-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber NZ-596585-A
titleOfInvention Isoxazolines as inhibitors of fatty acid amide hydrolase
abstract IP No. 596585 The present disclosure provides isoxazoline FAAH inhibitors of the formula (I): or pharmaceutically acceptable forms thereof, wherein each of G, Ra, Rb, Rc, and Rd are as defined herein. The present invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable form thereof, and a pharmaceutically acceptable excipient. The present invention also provides methods for treating an FAAH-mediated condition comprising administering a therapeutically effective amount of a compound of formula (I), or pharmaceutically acceptable form thereof, to a subject in need thereof. Conditions treated include a painful condition, an inflammatory condition, an immune disorder, a disorder of the central nervous system, a metabolic disorder, a cardiac disorder, glaucoma, neuropathic pain, central pain, deafferentiation pain, chronic pain, post–operative pain, preoperative pain, nociceptive pain, acute pain, non–inflammatory pain, inflammatory pain, pain associated with cancer, wound pain, burn pain, pain associated with medical procedures, pain resulting from pruritus, painful bladder syndrome, pain associated with premenstrual dysphoric disorder, pain associated with premenstrual syndrome, pain associated with chronic fatigue syndrome, pain associated with pre-term labor, pain associated with withdrawal symptoms from drug addiction, joint pain, arthritic pain, lumbosacral pain, musculo–skeletal pain, headache, migraine, muscle ache, lower back pain, neck pain, toothache dental/maxillofacial pain, visceral pain, a gastrointestinal disorder, a skin condition, neurotoxicity and/or neurotrauma, stroke, multiple sclerosis, spinal cord injury, epilepsy, a mental disorder, a sleep condition, a movement disorder, nausea and/or emesis, amyotrophic lateral sclerosis, Alzheimer’s disease, drug addiction, a wasting condition, an obesity-related condition and complication thereof, hypertension, circulatory shock, myocardial reperfusion injury and atherosclerosis
priorityDate 2009-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID396949
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID100911581
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425753601
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID11429245
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12304501
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID14073
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID338521
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID79152
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID2166
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID836565

Total number of triples: 75.